“Plaintiffs Acerta Pharma B.V., AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB (collectively, "AstraZeneca"), and Merck Sharp & Dohme B.V. ("MSD") (collectively, with AstraZeneca, "Plaintiffs"), and Defendants Cipla Limited and Cipla USA, Inc. (collectively, "Cipla") which are parties in the above-captioned action, have agreed to terms and conditions representing a negotiated settlement of this action and have set forth those terms and conditions in a Settlement Agreement (the "Settlement Agreement"). Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in this action as follows: IT IS this 12th day of June,2024 ;ORDERED, ADJUDGED AND DECREED as follows: This District Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over AstraZeneca, MSD, and Cipla. As used in this Consent Judgment, (i) the term "Cipla Products" shall mean the Generic Acalabrutinib Products that are sold, offered for sale or distributed pursuant to ANDA No. 216507, including any supplements or amendments thereto, (and defined in greater detail in the Settlement Agreement); and (ii) the term "Affiliate" shall mean, with respect to a Party, any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such Party. For purposes of this definition, "control" means (a) ownership, directly or through one or more intermediaries, of (i) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (ii) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the board of directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity. Except as specifically authorized pursuant to the Settlement Agreement, Cipla, including any of its Affiliates, successors and assigns, is enjoined from infringing U.S. Patent Nos. 9,796,721, 10,167,291, and 10,272,083, (the "Asserted Patents") on its own part or through any Affiliate, by making, having made, using, selling, offering to sell, importing or distributing of the Cipla Products. Compliance with this Consent Judgment may be enforced by AstraZeneca, MSD, and their successors in interest, or assigns, as permitted by the terms of the Settlement Agreement. 3. 4 Nothing in this Consent Judgment prohibits Cipla or its Affiliates from maintaining its existing Paragraph IV Certification to the Asserted Patents or prohibits FDA from granting final approval to Cipla’s ANDA. This District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement. All claims, affirmative defenses, and demands in this action between AstraZeneca, Merck, and Cipla, and only between AstraZeneca, Merck, and Cipla, are hereby dismissed without prejudice and without costs, disbursements or attorneys’ fees.”